Literature DB >> 6432726

Rectal administration of sodium valproate in children.

E Scanabissi, D Dal Pozzo, E Franzoni, C Galloni, G Mengoli, R Calivà.   

Abstract

A study of VPA based on a comparison of mean plasma levels, plasma peak latency times and plasma half-lives after rectal and oral administration was conducted in 9 children between 6 months and 10 years of age suffering from various forms of epileptic seizure, before they received chronic VPA treatment. Each child received an oral dose of 20 mg/kg and after two days a rectal dose of 20 mg/kg and the mean plasma concentrations were determined at intervals for both modes of administration. An identical plasma concentration for both after 24 h showed that the quantity of drug absorbed was the same. The mean half-life varied according to age: 11 +/- 2 h for children over 3 years of age and 9 +/- 1 h for those under 3. The results of the study, in line with the few other available published data, thus confirm the validity of rectal VPA administration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432726     DOI: 10.1007/bf02043222

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  13 in total

1.  Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism.

Authors:  Y Godin; L Heiner; J Mark; P Mandel
Journal:  J Neurochem       Date:  1969-06       Impact factor: 5.372

2.  Absorption rate and bioavailability of valproic acid and its sodium from rectal dosage forms.

Authors:  F Moolenaar; W J Greving; T Huizinga
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

3.  The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers.

Authors:  V Nitsche; H Mascher
Journal:  Epilepsia       Date:  1982-04       Impact factor: 5.864

Review 4.  Drug therapy: Valproic acid.

Authors:  J Koch-Weser; T R Browne
Journal:  N Engl J Med       Date:  1980-03-20       Impact factor: 91.245

5.  Rectal administration of sodium valproate in status epilepticus.

Authors:  F J Vajda; G W Mihaly; J L Miles; G A Donnan; P F Bladin
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

6.  Steady-state kinetics of valproic acid in epileptic patients.

Authors:  J Bruni; B J Wilder; L J Willmore; R J Perchalski; H J Villarreal
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

7.  Pharmacokinetics of di-n-propylacetate in epileptic patients.

Authors:  F Schobben; E van der Kleijn; F J Gabreëls
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

8.  Pharmacology of valproic acid in children with severe epilepsy: clearance and hepatotoxicity.

Authors:  W E Dodson; V Tasch
Journal:  Neurology       Date:  1981-08       Impact factor: 9.910

9.  Bioavailability of rectally administered valproic acid syrup.

Authors:  J C Cloyd; R L Kriel
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

10.  Valproic acid dosage and plasma protein binding and clearance.

Authors:  A T Bowdle; I H Patel; R H Levy; A J Wilensky
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

View more
  3 in total

Review 1.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

2.  Bioavailability of sodium valproate suppositories during repeated administration at steady state in epileptic children.

Authors:  J Issakainen; B F Bourgeois
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

Review 3.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.